Chronic Lymphocytic Leukemia

Clinical Trials

Below is a list of Chronic Lymphocytic Leukemia clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Phase II Study of Sunitinib Malate (Sutent) for Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Patients are being asked to take part in this research study because they have lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Sunitinib is an investigational anti-cancer agent that has not yet been approved by the U.S. Food and Drug Administration for use in CLL and SLL. This medication blocks a signaling pathway in tumor cells called the "VEGF pathway." In the laboratory, this pathway has been shown to be abnormal in CLL B-cells and to be used by these leukemia cells to prolong their survival. It is hoped that blocking this signaling pathway will lead to the death of CLL cells and improvement in the patient's condition.
Read more

MC0785, Antibody Therapy with Alemtuzumab (Campath), Rituximab (Rituxan), and GMCSF (Sargramostim) for Initial Treatment of High Risk Chronic Lymphocytic Leukemia (CLL)
Patients are being asked to take part in this research study because they have been diagnosed with chronic lymphocytic leukemia (CLL). This study is being done to see how their disease responds to treatment.
Read more

Phase 2 Study to Evaluate the Safety and Efficacy of Monoclonal Antibody Lumiliximab in Combination with Fludarabine, Cyclophosphamide (Cytoxan), and Rituximab (Rituxan) Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
Patients are being asked to take part in this research study because their doctor has tested the patient's blood and/or bone marrow and determined that they have a diagnosis of relapsed Chronic Lymphocytic Leukemia (CLL). The purpose of the study is to compare the clinical benefit of Lumiliximab in combination with Fludarabine, Cyclophosphamide, and Rituximab (FCR) to FCR alone and to compare the safety of Lumiliximab when given in combination with FCR to FCR alone. This will include looking at what side effects occur and how often they occur.
Lumiliximab is an investigational drug made by Biogen Idec Inc. (Biogen Idec) that is
being studied for the treatment of relapsed chronic lymphocytic leukemia (CLL). Regulatory authorities have not yet approved lumiliximab for general use, but they have allowed it for use in clinical trials. Lumiliximab is a monoclonal antibody made of monkey and human proteins. A monoclonal antibody is a substance made in the laboratory that binds to a specific protein. Although doctors don't know exactly how lumiliximab works, it is believed that lumiliximab binds to a protein on CLL cells and causes them to die.
At the time of this summary, a total of 257 patients have received lumiliximab. This includes patients with CLL as well as patients with allergic disorders. In clinical trials in patients with CLL, lumiliximab has been given alone as well as with fludarabine, cyclophosphamide, and rituximab (FCR), a drug combination frequently used to treat people with CLL.
Fludarabine is a type of chemotherapy drug, which has been approved for the treatment of patients with CLL. Cyclophosphamide is another approved chemotherapy drug often given with fludarabine. Rituximab is a monoclonal antibody made of mouse and human proteins. It attaches to a specific protein found on most CLL cells. Rituximab has been approved in the US, Canada, and Europe for the treatment of some cancers. Although rituximab is commonly used for the treatment of CLL, it has not been approved for this disease.
Read more

A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia
The purpose of this research study is to evaluate the use of CpG 7909. CpG 7909 is a short strand of DNA, the genetic material found in cells. CpG 7909 has the potential to stimulate the immune system, and we are studying these effects to learn if CpG 7909 has potentially beneficial effects in people with chronic lymphocytic leukemia. The purpose of this research study is to see if we can measure biological changes in Chronic Lymphocytic Leukemia (CLL) cells and chemicals in your blood after receiving CpG 7909.
Read more

Daily Oral Polyphenon E in Asymptomatic Rai Stage 0-II Patients with Chronic Lymphocytic Leukemia (MC0419)
This research study is being done to:

• test the effects (good and bad) of an extract of green tea (called polyphenon E) on patients who have chronic lymphocytic leukemia (CLL);
• find the highest dose of polyphenon E that can be given without causing unacceptable bad side effects;
• learn how the body handles or processes polyphenon E and polyphenon Es other effects in the body using blood and bone marrow samples.

There is no approved treatment for patients who don't have obvious signs or symptoms of their early stage CLL, despite the fact that the cancer gets worse in many patients with this illness, and in time will require treatment for it.
Read more

Genetic Epidemiology of Chronic Lymphocytic Leukemia (CLL)
Research has consistently shown that patients with at least one blood relative with chronic lymphocytic leukemia (CLL) have over two times greater risk of getting CLL compared to the general population. These findings strongly suggest that genetics play a role in the development of CLL. As such, the purpose of this study is to identify the genes that increase the risk of developing CLL. To do this, we need families that have multiple individuals diagnosed with CLL, i.e., CLL families. CLL families are a very valuable resource that will enable us to better understand the genetic basis of this cancer. Because CLL families are rare, we have formed a U.S. collaboration to identify these families, known as the Genetic Epidemiology of CLL (GEC) Consortium. This consortium is funded by the National Cancer Institute and includes investigators from Mayo Clinic, M.D. Anderson Cancer Center, National Cancer Institute, UCSD, and University of Minnesota. The completion of this study will advance our understanding of how CLL develops and should ultimately help identify new approaches for the prevention of CLL.
Read more

MC0784, Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (Rituxan) followed by Consolidation with Lenalidomide (Revlimid) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Patients are being asked to take part in this research study because they have previously untreated B-cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). This study is being done to learn about the effectiveness and side effects of pentostatin, cyclophosphamide and rituximab (PCR) followed by lenalidomide for previously untreated CLL/SLL and to learn whether lenalidomide treatment after treatment with PCR can eliminate residual CLL/SLL that remains after PCR.
Read more

Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia
This research study is being done to see if patients who are treated with this drug combination will go into remission (a complete or partial disappearance of the disease), and if the remission will be maintained with CAMPATH-1H treatment.
Read more